What brain measurements reveal about hand and walking changes in isolated REM sleep behavior disorder

Since the previous research note · Earlier expectation not tested

Track continuity

Since the previous research note: What follow-up revealed after a sleep disorder that makes people act out dreams

Previous expectation: A reproducible MRI marker might help researchers assemble more comparable groups for early Parkinson's treatment trials if it predicts future disease beyond clinical measures across patients and imaging settings.

What this study adds: The December 3, 2025 study adds cross-sectional tissue measurements, clinical correlations and patient subgroup comparisons alongside ALPS. It does not test the earlier forecast's prospective prediction or trial-recruitment capability.

---

What changed in this study

A person can have isolated REM sleep behavior disorder (iRBD) long before everyday independence visibly changes. During this sleep disorder, the body may act out dreams, while clinical testing can still reveal small differences in movement, thinking, smell, or other functions. That combination creates a difficult question: are these early signs simply part of the disorder, or are they clues to a neurological illness that may appear later?

A study published December 3, 2025, examined that question through brain-tissue measurements rather than a future diagnosis. Researchers compared 44 people with a sleep-study-confirmed iRBD diagnosis with 52 healthy controls. The participants completed clinical and neurological testing and underwent diffusion MRI, a technique that estimates features of tissue microstructure from the movement of water in the brain.

The results connected several imaging measurements with subtle differences in hand dexterity, turning while walking, and sleep quality. They also identified a more clinically affected subgroup whose perivascular diffusion measurement differed from controls. But the study captured one point in time. It did not follow participants to see who later developed Parkinson’s disease, dementia with Lewy bodies, multiple system atrophy, or another form of Parkinsonism. The scans therefore describe changes already present in some people with iRBD; they do not yet forecast an individual’s neurological future.

Subtle clinical differences accompanied largely preserved daily independence

Compared with controls, the iRBD group reported poorer sleep and showed several subtle motor differences. They took longer on a hand-dexterity task involving the placement of pegs and made more steps during 10-meter walking tests at normal and maximum speed. Other walking measures also differed, including arm-swing amplitude, walking velocity, asymmetry, and stride length during single-task and dual-task tests.

The pattern was important because the changes were detectable without amounting to substantial everyday disability. Scores assessing daily functional autonomy remained low, suggesting that the participants could largely manage ordinary activities even while testing picked up differences in movement. The study also found cognitive and non-motor differences within the iRBD sample, including alterations in executive, memory, and visuospatial performance. Loss of smell was the most frequent non-motor sign reported in the patient group, followed by constipation and urinary dysfunction.

This is the clinical background for reading the scans. The imaging findings were not floating abnormalities in people with no observable differences at all. They appeared alongside small, measurable changes in sleep, movement, and other functions. At the same time, the study was not designed to determine whether any one finding would later become a specific neurological diagnosis.

Two measurements ask different questions of brain tissue

One measurement was the orientation dispersion index, or ODI. Diffusion MRI can estimate how widely the extensions of nerve cells are oriented within a region. ODI summarizes the spread of those directions. A lower value means the estimated orientations are less dispersed, or more coherent. That may reflect a change in tissue organization, but it is not a direct cell count and does not by itself identify which biological process produced the pattern.

The authors also used a measurement called the DTI-ALPS index. DTI-ALPS compares water diffusivity along the direction of spaces that run beside blood vessels with diffusivity in other nearby fiber directions, using a brain slice at the level of the body of the lateral ventricle. The aim is to obtain an indirect estimate related to movement of water along perivascular spaces, which are spaces alongside blood vessels in brain tissue.

The two measures therefore address different features. ODI concerns the estimated geometry of tissue structures. DTI-ALPS is a comparison of water movement along selected anatomical directions near blood vessels. Neither measurement directly counts dying neurons, demonstrates protein accumulation, or measures the removal of a specific protein. A change in either index can arise from how tissue organization and water movement are represented in the imaging model.

The study used NODDI, a diffusion approach that models intra-neuritic water, extra-neuritic water, and cerebrospinal fluid as separate compartments. It derived ODI, intracellular volume fraction, and isotropic water diffusion measures, allowing the researchers to examine both gray and white matter. The analysis also illustrates why a single diffusion number is not a simple readout of brain health: different tissue features can move in different directions, and one may change before another.

The signal depended on how the analysis divided the brain

In gray matter, people with iRBD had significantly lower ODI than controls in frontal and parietal regions. Both the spatial and regional analyses detected differences. These findings do not establish a single uniform lesion or a precisely localized disease pathway.

The white-matter results required more qualification. In the voxelwise tract-based analysis, ODI differences approached statistical significance in several pathways, including parts of the cerebellar peduncle, medial lemniscus, corona radiata, and internal and external capsules, but the reported threshold was not met. A separate regional analysis did find significantly reduced ODI in the brainstem and in a frontal-lobe region. Fractional anisotropy and intracellular volume fraction did not show significant group differences in the gray- or white-matter maps described here.

That analytical split matters. A regional comparison can detect an average difference across an anatomical area even when a finer voxel-by-voxel analysis does not produce a statistically significant result. The findings support a cautious description of altered tissue organization, especially in gray matter and selected regional white matter. They do not justify treating every highlighted tract as a confirmed abnormality.

The authors also offer a biological reason why ODI might change without a corresponding change in other diffusion measures. In tissue with crossing fiber architecture, the selective loss of one fiber population or pruning of collateral projections could leave the remaining directions more coherent. A lower ODI could therefore appear before a measurable reduction in intracellular volume fraction. Fractional anisotropy can combine several microstructural influences, so a change in directional dispersion might offset another subtle change and leave the overall FA comparison nonsignificant.

The water-diffusion measure was lower in the more affected pattern

Across the full iRBD group, the DTI-ALPS index was significantly lower than in controls. The authors interpreted this as consistent with altered glymphatic functionality, using glymphatic to refer to a proposed fluid-transport system associated with perivascular spaces. The measurement is indirect and model-dependent, so it is better understood as a diffusion-based proxy than as a direct observation of fluid clearance.

The clinical associations gave the imaging results a more recognizable shape. Within the iRBD group, lower gray-matter ODI in a frontal region correlated with lower peak turning velocity during a timed walking task that also required a cognitive component. It also correlated with higher scores on a motor examination. Lower ODI in a parietal region correlated with poorer sleep-quality scores and more time needed to complete the peg-placement task.

These correlations do not show that a tissue measurement caused a person to turn more slowly, sleep worse, or handle pegs less quickly. They show that the estimated tissue organization and selected clinical measures varied together after the analysis adjusted for age and sex and corrected the correlation results for multiple comparisons. The practical value of the result is that a subtle imaging difference was related to actions that can be observed and measured, rather than remaining an entirely abstract scan feature.

Patient profiles separated into two different patterns

The researchers then used demographic, sleep, motor, cognitive, mood, and other clinical variables to divide the iRBD participants into data-driven groups. The analysis identified one cluster of 25 people and another of 15, while four participants were not included in either cluster. Internal measures supported a two-cluster solution, and bootstrap resampling was used to examine how stable that grouping was within the available dataset.

The smaller cluster was older and generally showed more pronounced clinical differences. It had worse sleep-related scores, more daytime sleepiness, poorer cognitive performance in several measures, and more affected walking during tasks that required either a single activity or an added cognitive demand. Constipation and urinary dysfunction were also more common in this group. The other cluster had a relatively less affected profile, although both clusters represented people with iRBD rather than a healthy and a diseased group.

Only the more affected cluster showed a significantly lower DTI-ALPS index than controls. That result is compatible with the possibility that perivascular diffusion differences are more apparent in a clinically more affected pattern. It does not establish a statistically significant difference between the two iRBD clusters themselves. A finding that separates one cluster from controls is not automatically evidence that the two patient clusters differ on that measurement.

The clustering is also not a forecast model. Resampling the same study population can show whether a grouping is reasonably stable under repeated sampling from that dataset, but it does not test the grouping in a separate cohort. The study did not establish a scan threshold that could tell one person what diagnosis they will eventually receive or when that diagnosis might occur.

What the scans can and cannot say about progression

The broader clinical context makes the need for better markers understandable. Many people with iRBD eventually develop an alpha-synuclein-related neurodegenerative condition, but the timing and form of that change vary. Clinical assessments alone cannot reliably identify the future diagnosis and trajectory for every person. A measurement that captures differences before obvious disability would therefore be valuable if it added dependable information over time.

This study reached an earlier point on that path. It found cross-sectional associations among iRBD, subtle clinical differences, diffusion-derived tissue features, and a lower DTI-ALPS index. It did not observe subsequent conversion, compare eventual diagnoses, or test whether the imaging measures predicted those outcomes beyond clinical assessment. Nor did it show that changing sleep, perivascular fluid movement, or any related biological process would prevent disease or improve treatment results.

Several features make restraint especially important. The sample was small, the patient group included more men than the controls, and the analyses covered many clinical and imaging variables. Some white-matter findings were trends rather than statistically significant results, and subgroup observations were exploratory. The DTI-ALPS metric is an indirect approximation of glymphatic function and cannot capture the full complexity of that system. Longitudinal studies with larger groups and independent validation are needed to determine whether these measurements can distinguish future neurological trajectories.

For someone diagnosed with iRBD, the most accurate reading is therefore present-tense. The scans may reveal subtle differences in tissue organization and perivascular diffusion that accompany measurable changes in movement or sleep. They add detail to the picture of what is happening now, while leaving the timing, type, and even individual course of later Parkinsonism unresolved.

What these scans could mean for earlier neurological care.

Combined tissue and perivascular diffusion measurements could eventually help clinicians distinguish different trajectories among people with confirmed isolated REM sleep behavior disorder. That could make follow-up conversations, monitoring decisions, and future planning more informative for patients and clinicians, especially when scan findings are interpreted alongside movement, sleep, cognitive, and non-motor assessments.

That benefit remains conditional. Prospective studies would need to show that the measurements predict later outcomes reliably, work in independent patient groups, and provide useful information beyond a careful clinical assessment. If those tests succeed, imaging could become one part of a more individualized understanding of early neurological change. This December 2025 study provides a detailed description of present heterogeneity; it does not yet provide a personal prognosis or a recommended scanning schedule.

Key Sources

• Primary source: Unveiling hidden neurodegeneration in isolated REM sleep behavior disorder through MRI microstructure and glymphatic flow.
  DOI or Journal Page · Peer-Reviewed Paper · 2025-12-03